Cargando…

Preparation and characterization of antibody-drug conjugates acting on HER2-positive cancer cells

Two systems of antibody-drug conjugates (ADCs), noncleavable H32-DM1 and cleavable H32-VCMMAE, were developed by using different linkers and drugs attached to the anti-HER2 antibody H32, which is capable of cell internalization. Activated functional groups, including an N-hydroxysuccinimidyl (NHS) e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chiang, Zu-Chian, Chiu, Yi-Kai, Lee, Cheng-Chung, Hsu, Nai-Shu, Tsou, Yueh-Liang, Chen, Hong-Sen, Hsu, Horng-Ru, Yang, Tzung-Jie, Yang, An-Suei, Wang, Andrew H. -J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521679/ https://www.ncbi.nlm.nih.gov/pubmed/32986768 http://dx.doi.org/10.1371/journal.pone.0239813

Ejemplares similares

Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models
por: Kuo, Wei-Ying, et al.
Publicado: (2018)

Effective binding to protein antigens by antibodies from antibody libraries designed with enhanced protein recognition propensities
por: Jian, Jhih-Wei, et al.
Publicado: (2019)

Noninvasive assessment of characteristics of novel anti-HER2 antibodies by molecular imaging in a human gastric cancer xenograft-bearing mouse model
por: Kuo, Wei-Ying, et al.
Publicado: (2018)

High throughput cytotoxicity screening of anti-HER2 immunotoxins conjugated with antibody fragments from phage-displayed synthetic antibody libraries
por: Hou, Shin-Chen, et al.
Publicado: (2016)

Eradicating mesothelin-positive human gastric and pancreatic tumors in xenograft models with optimized anti-mesothelin antibody–drug conjugates from synthetic antibody libraries
por: Hsu, Hung-Ju, et al.
Publicado: (2021)

High throughput discovery of influenza virus neutralizing antibodies from phage-displayed synthetic antibody libraries
por: Chen, Ing-Chien, et al.
Publicado: (2017)

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
por: Ocaña, Alberto, et al.
Publicado: (2020)

A panel of anti-influenza virus nucleoprotein antibodies selected from phage-displayed synthetic antibody libraries with rapid diagnostic capability to distinguish diverse influenza virus subtypes
por: Yu, Chung-Ming, et al.
Publicado: (2020)

Antibody-drug conjugates in HER2-positive breast cancer
por: Li, Lixi, et al.
Publicado: (2022)

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
por: Gandullo‐Sánchez, Lucía, et al.
Publicado: (2020)

Click Chemistry and Multicomponent Reaction for Linker Diversification of Zinc Dipicolylamine-Based Drug Conjugates
por: Tsai, Ching-Hua, et al.
Publicado: (2022)

Polyethylene glycol-conjugated HER2-targeted peptides as a nuclear imaging probe for HER2-overexpressed gastric cancer detection in vivo
por: Guan, Siao-Syun, et al.
Publicado: (2018)

Identifying HER2 Inhibitors from Natural Products Database
por: Yang, Shun-Chieh, et al.
Publicado: (2011)

Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer
por: Najjar, Mariana K., et al.
Publicado: (2022)

Long-acting antibody ligand mimetics for HER4-selective agonism
por: Shan, Lu, et al.
Publicado: (2020)

Therapeutic potential of an anti-HER2 single chain antibody–DM1 conjugates for the treatment of HER2-positive cancer
por: Zhang, Hang, et al.
Publicado: (2017)

Dendrimer antibody conjugate to target and image HER-2 overexpressing cancer cells
por: Otis, James B., et al.
Publicado: (2016)

Novel development strategies and challenges for anti-Her2 antibody-drug conjugates
por: Zhang, Xinling, et al.
Publicado: (2022)

Advances in Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer
por: Yu, Yongchao, et al.
Publicado: (2022)

Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors
por: McNamara, Blair, et al.
Publicado: (2023)

Bispecific Antibody Conjugated Manganese-Based Magnetic Engineered Iron Oxide for Imaging of HER2/neu- and EGFR-Expressing Tumors
por: Wu, Shou-Cheng, et al.
Publicado: (2016)

Daily Aspirin Reduced the Incidence of Hepatocellular Carcinoma and Overall Mortality in Patients with Cirrhosis
por: Lee, Chern-Horng, et al.
Publicado: (2023)

PREPARATION OF ANTIBODY-FERRITIN CONJUGATES FOR IMMUNO-ELECTRON MICROSCOPY
por: Ram, J. Sri, et al.
Publicado: (1963)

Mechanism of Antigen Presentation and Specificity of Antibody Cross-Reactivity Elicited by an Oligosaccharide-Conjugate Cancer Vaccine
por: Wang, Szu-Wen, et al.
Publicado: (2023)

HER2-/HER3-Targeting Antibody—Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors
por: Yonesaka, Kimio
Publicado: (2021)

Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates
por: Albarrán, Víctor, et al.
Publicado: (2022)

Engineering a HER2-specific antibody-drug conjugate to increase lysosomal delivery and therapeutic efficacy
por: Kang, Jeffrey C., et al.
Publicado: (2019)

HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
por: Rinnerthaler, Gabriel, et al.
Publicado: (2019)

Impact of Maleimide Disubstitution on Chemical and Biological Characteristics of HER2 Antibody–Drug Conjugates
por: Feuillâtre, Ofelia, et al.
Publicado: (2020)

Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer
por: Rassy, Elie, et al.
Publicado: (2022)

Thrombopoietin Receptor Agonists for Thrombocytopenia Secondary to HER2-Targeted Antibody Drug Conjugates
por: Rainone, Michael, et al.
Publicado: (2023)

A Novel Preparation Method for Camptothecin (CPT) Loaded Folic Acid Conjugated Dextran Tumor-Targeted Nanoparticles
por: Zu, Yuangang, et al.
Publicado: (2011)

Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression
por: Koyama, Kumiko, et al.
Publicado: (2022)

Generation of a Novel SORT1×HER2 Bispecific Antibody–Drug Conjugate Targeting HER2-Low-Expression Tumor
por: Zhuang, Weiliang, et al.
Publicado: (2023)

Antibody CDR amino acids underlying the functionality of antibody repertoires in recognizing diverse protein antigens
por: Peng, Hung-Pin, et al.
Publicado: (2022)

Antibody–PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4
por: Maneiro, María, et al.
Publicado: (2020)

Quantum Dots: Synthesis, Antibody Conjugation, and HER2-Receptor Targeting for Breast Cancer Therapy
por: Fatima, Iqra, et al.
Publicado: (2021)

Research progress of antibody-drug conjugates therapy for HER2-low expressing gastric cancer
por: Yu, Minghui, et al.
Publicado: (2023)

HER2-targeted antibody–drug conjugates for breast cancer: ancestry and dose adjustment for thrombocytopenia
por: Rainone, Michael, et al.
Publicado: (2023)

Phase I study of A166, an antibody‒drug conjugate in advanced HER2-expressing solid tumours
por: Zhang, Jian, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_otmn6ftjcel7fpq7i84tn6ios6